Healthcare / Drug Manufacturers - Specialty & GenericASX
$0.04
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 20%
FCF escenarios
weak_data · normalized FCF $-8.4M · quality 55.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
21/100
D
Piotroski
1/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$16M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-36.8%
↓Gross Margin
68.2%
↑Debt/Equity
0.48
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+16.7%
FCF CAGR
—
FCF margin
-39.3%
FCF / Net income
0.94x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $19.2M · net income $-8.1M · FCF $-7.6M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $19.2M | $19.2M | $13.2M | $6.9M | $12.1M |
| Net Income | $-8.1M | $-8.1M | $-5.4M | $-8.5M | $-1.2M |
| EBITDA | $-6.4M | $-6.4M | $-5.0M | $-8.8M | $-365000.00 |
| EPS | -0.02 | -0.02 | -0.02 | -0.03 | -0.00 |
| Gross Margin | 68.2% | 68.2% | 78.8% | 68.6% | 88.1% |
| Operating Margin | -41.4% | -41.4% | -51.8% | -142.4% | -15.7% |
| Net Margin | -42.0% | -42.0% | -40.9% | -122.5% | -9.6% |
| Balance Sheet | |||||
| Debt/Equity | 0.48 | 0.48 | 0.19 | 0.03 | 0.03 |
| Current Ratio | 2.97 | 2.97 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-7.6M | $-7.6M | $-10.3M | $-8.4M | $1.9M |
| Returns | |||||
| ROE | -36.8% | -36.8% | -23.1% | -35.2% | -4.3% |
| Valuation | |||||
| P/B | 0.72 | 0.72 | 1.63 | 0.65 | 1.28 |
| Growth & Yield | |||||
| Revenue Growth | 45.3% | 45.3% | 90.7% | -42.7% | — |
| EPS Growth | -21.9% | -21.9% | 54.3% | -596.0% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-61.9%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.02 → -0.02
Residual
-61.9%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.